Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Salarius Pharmaceuticals, Inc. (FLKS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/05/2023 |
4
| Lieber Jonathan I (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| McCreedy Bruce J Jr. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| HANISH ARNOLD C (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| Lammers Paul (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| Burleson Tess (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| McVicar William K. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 1,440 shares
@ $0 |
|
| 01/05/2023 |
4
| Rosenblum Mark J (Exec VP Finance, CFO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 8,000 shares
@ $0 |
|
| 01/05/2023 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 20,000 shares
@ $0 |
|
| 11/07/2022 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 shares
@ $1.734, valued at
$17.3k
|
|
| 11/07/2022 |
4
| Rosenblum Mark J (Exec VP Finance, CFO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 7,314 shares
@ $1.734, valued at
$12.7k
|
|
| 06/08/2022 |
4
| Burleson Tess (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Bought 27,700 shares
@ $0.18, valued at
$5k
|
|
| 06/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2022 |
4
| McVicar William K. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Bought 26,553 shares
@ $0.1883, valued at
$5k
|
|
| 06/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/31/2022 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Bought 3,400 shares
@ $0.18, valued at
$612
Bought 18,600 shares
@ $0.182, valued at
$3.4k
Bought 708 shares
@ $0.18, valued at
$127.4
Bought 10,392 shares
@ $0.1799, valued at
$1.9k
Bought 10,800 shares
@ $0.1843, valued at
$2k
|
|
| 05/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2022 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 shares
@ $0.1863, valued at
$1.9k
|
|
| 05/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/09/2022 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Bought 139,488 shares
@ $0.391, valued at
$54.5k
|
|
| 01/21/2022 |
4
| McCreedy Bruce J Jr. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 01/21/2022 |
4
| Lieber Jonathan I (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 01/21/2022 |
4
| McVicar William K. (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 01/21/2022 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 500,000 options to buy
@ $0.48, valued at
$240k
|
|
| 01/21/2022 |
4
| Burleson Tess (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 01/21/2022 |
4
| HANISH ARNOLD C (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 01/21/2022 |
4
| Lammers Paul (Director) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 01/21/2022 |
4
| Rosenblum Mark J (Exec VP Finance, CFO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 200,000 options to buy
@ $0.48, valued at
$96k
|
|
| 11/05/2021 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 7,939 shares
@ $0.718, valued at
$5.7k
|
|
| 11/05/2021 |
4
| Rosenblum Mark J (Exec VP Finance, CFO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 7,787 shares
@ $0.718, valued at
$5.6k
|
|
| 08/17/2021 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Bought 2,000 shares
@ $0.899, valued at
$1.8k
Bought 2,000 shares
@ $0.892, valued at
$1.8k
|
|
| 08/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/05/2021 |
4
| Arthur David J. (CEO) has filed a Form 4 on Salarius Pharmaceuticals, Inc.|
Txns:
| Granted 9,822 shares
@ $0.567, valued at
$5.6k
|
|
|
|
|